

## Critical Medicines Act: a decisive step towards European health sovereignty – now let's deliver

The European Fine Chemicals Group (EFCG) welcomes the provisional agreement reached between the European Council and the European Parliament on the Critical Medicines Act (CMA) on 12 May 2026. This agreement represents a key milestone in strengthening Europe's security of supply for critical medicines, to the direct benefit of European patients.

By explicitly recognising the need to foster local, sustainable and resilient production, notably through the introduction of resilience-related requirements in public procurement for critical medicines and their active pharmaceutical ingredients (APIs), the CMA clearly moves in the right direction. It acknowledges the strategic role of European manufacturing capacity in securing supply chains and reducing dependencies on non-EU countries.

EFCG welcomes this agreement as a crucial starting point. Its effective and concrete implementation in the coming months will be essential to deliver on its ambitions. Particular attention must be given to:

- the timely and coherent use of the Union list of critical medicines in implementation measures
- the effective integration of strong resilience and EU preference criteria into public procurement procedures at Member State level
- the consistent deployment of support schemes for strategic industrial projects.

European manufacturers of active pharmaceutical ingredients, intermediates and key inputs are well placed to meet this challenge and are dedicated to working with Commission and Member States to reach these goals. They have the industrial know-how, the highest quality standards and the innovation capabilities required to secure long-term supply for the European market, while meeting social, environmental and economic expectations.

*"The Critical Medicines Act finally establishes a political framework recognising that European health sovereignty depends on strong manufacturing anchored in Europe. The focus must now shift to delivery. The members of EFCG remain fully committed to supporting European and national policy makers to make the CMA a tangible success for European patients,"* stated Steffen Denzinger, President of EFCG.

For more information please contact:

Michela Mastrantonio, [mim@cefic.be](mailto:mim@cefic.be),

Alice Salmon, [asa@cefic.be](mailto:asa@cefic.be),

Mathilde Graas, [mgr@cefic.be](mailto:mgr@cefic.be)

To know more about EFCG, please visit [www.efcg.cefic.org](http://www.efcg.cefic.org)

**EFCG**

Rue Belliard 40 box 15 B-1040 Brussels Belgium  
[www.efcg.cefic.org](http://www.efcg.cefic.org)

**A sector group of Cefic** 

European Chemical Industry Council - Cefic aisbl

EU Transparency Register n° 64879142323-90

